Drugs for Oncology Market, Global Outlook and Forecast 2022-2028

April 2022 | 110 pages | ID: D722F647B4FEEN
Market Monitor Global

Abstracts

Cancer is the name given to a group of related diseases characterized by the uncontrolled and excessive growth of abnormal cells. More than 200 different types of cancer have been identified.

This report contains market size and forecasts of Drugs for Oncology in Global, including the following market information:

Global Drugs for Oncology Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Drugs for Oncology market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Drugs for Oncology include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Drugs for Oncology companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Drugs for Oncology Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Drugs for Oncology Market Segment Percentages, by Type, 2021 (%)

• Chemotherapy
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy
• Others

Global Drugs for Oncology Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Drugs for Oncology Market Segment Percentages, by Application, 2021 (%)

• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Respiratory/Lung Cancer
• Others

Global Drugs for Oncology Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Drugs for Oncology Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Drugs for Oncology revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Drugs for Oncology revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Roche
• Celgene
• Novartis
• Bristol-Myers Squibb
• Johnson & Johnson
• Merck & Co.
• AstraZeneca
• Pfizer
• Amgen
• Eli Lilly
• AbbVie
• Takeda
• Astellas
• Ipsen
• Sanofi
• Bayer
• Biogen Idec
• Teva
• Otsuka
• Eisai
• Merck KGaA
• Gilead Sciences

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

1.1 Drugs for Oncology Market Definition
1.2 Market Segments
  1.2.1 Market by Type
  1.2.2 Market by Application
1.3 Global Drugs for Oncology Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
  1.5.1 Research Methodology
  1.5.2 Research Process
  1.5.3 Base Year
  1.5.4 Report Assumptions & Caveats

2 GLOBAL DRUGS FOR ONCOLOGY OVERALL MARKET SIZE

2.1 Global Drugs for Oncology Market Size: 2021 VS 2028
2.2 Global Drugs for Oncology Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
  2.3.1 Market Opportunities & Trends
  2.3.2 Market Drivers
  2.3.3 Market Restraints

3 COMPANY LANDSCAPE

3.1 Top Drugs for Oncology Players in Global Market
3.2 Top Global Drugs for Oncology Companies Ranked by Revenue
3.3 Global Drugs for Oncology Revenue by Companies
3.4 Top 3 and Top 5 Drugs for Oncology Companies in Global Market, by Revenue in 2021
3.5 Global Companies Drugs for Oncology Product Type
3.6 Tier 1, Tier 2 and Tier 3 Drugs for Oncology Players in Global Market
  3.6.1 List of Global Tier 1 Drugs for Oncology Companies
  3.6.2 List of Global Tier 2 and Tier 3 Drugs for Oncology Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview
  4.1.1 by Type - Global Drugs for Oncology Market Size Markets, 2021 & 2028
  4.1.2 Chemotherapy
  4.1.3 Targeted Therapy
  4.1.4 Immunotherapy (Biologic Therapy)
  4.1.5 Hormonal Therapy
  4.1.6 Others
4.2 By Type - Global Drugs for Oncology Revenue & Forecasts
  4.2.1 By Type - Global Drugs for Oncology Revenue, 2017-2022
  4.2.2 By Type - Global Drugs for Oncology Revenue, 2023-2028
  4.2.3 By Type - Global Drugs for Oncology Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview
  5.1.1 By Application - Global Drugs for Oncology Market Size, 2021 & 2028
  5.1.2 Blood Cancer
  5.1.3 Breast Cancer
  5.1.4 Gastrointestinal Cancer
  5.1.5 Prostate Cancer
  5.1.6 Respiratory/Lung Cancer
  5.1.7 Others
5.2 By Application - Global Drugs for Oncology Revenue & Forecasts
  5.2.1 By Application - Global Drugs for Oncology Revenue, 2017-2022
  5.2.2 By Application - Global Drugs for Oncology Revenue, 2023-2028
  5.2.3 By Application - Global Drugs for Oncology Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Drugs for Oncology Market Size, 2021 & 2028
6.2 By Region - Global Drugs for Oncology Revenue & Forecasts
  6.2.1 By Region - Global Drugs for Oncology Revenue, 2017-2022
  6.2.2 By Region - Global Drugs for Oncology Revenue, 2023-2028
  6.2.3 By Region - Global Drugs for Oncology Revenue Market Share, 2017-2028
6.3 North America
  6.3.1 By Country - North America Drugs for Oncology Revenue, 2017-2028
  6.3.2 US Drugs for Oncology Market Size, 2017-2028
  6.3.3 Canada Drugs for Oncology Market Size, 2017-2028
  6.3.4 Mexico Drugs for Oncology Market Size, 2017-2028
6.4 Europe
  6.4.1 By Country - Europe Drugs for Oncology Revenue, 2017-2028
  6.4.2 Germany Drugs for Oncology Market Size, 2017-2028
  6.4.3 France Drugs for Oncology Market Size, 2017-2028
  6.4.4 U.K. Drugs for Oncology Market Size, 2017-2028
  6.4.5 Italy Drugs for Oncology Market Size, 2017-2028
  6.4.6 Russia Drugs for Oncology Market Size, 2017-2028
  6.4.7 Nordic Countries Drugs for Oncology Market Size, 2017-2028
  6.4.8 Benelux Drugs for Oncology Market Size, 2017-2028
6.5 Asia
  6.5.1 By Region - Asia Drugs for Oncology Revenue, 2017-2028
  6.5.2 China Drugs for Oncology Market Size, 2017-2028
  6.5.3 Japan Drugs for Oncology Market Size, 2017-2028
  6.5.4 South Korea Drugs for Oncology Market Size, 2017-2028
  6.5.5 Southeast Asia Drugs for Oncology Market Size, 2017-2028
  6.5.6 India Drugs for Oncology Market Size, 2017-2028
6.6 South America
  6.6.1 By Country - South America Drugs for Oncology Revenue, 2017-2028
  6.6.2 Brazil Drugs for Oncology Market Size, 2017-2028
  6.6.3 Argentina Drugs for Oncology Market Size, 2017-2028
6.7 Middle East & Africa
  6.7.1 By Country - Middle East & Africa Drugs for Oncology Revenue, 2017-2028
  6.7.2 Turkey Drugs for Oncology Market Size, 2017-2028
  6.7.3 Israel Drugs for Oncology Market Size, 2017-2028
  6.7.4 Saudi Arabia Drugs for Oncology Market Size, 2017-2028
  6.7.5 UAE Drugs for Oncology Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Roche
  7.1.1 Roche Corporate Summary
  7.1.2 Roche Business Overview
  7.1.3 Roche Drugs for Oncology Major Product Offerings
  7.1.4 Roche Drugs for Oncology Revenue in Global Market (2017-2022)
  7.1.5 Roche Key News
7.2 Celgene
  7.2.1 Celgene Corporate Summary
  7.2.2 Celgene Business Overview
  7.2.3 Celgene Drugs for Oncology Major Product Offerings
  7.2.4 Celgene Drugs for Oncology Revenue in Global Market (2017-2022)
  7.2.5 Celgene Key News
7.3 Novartis
  7.3.1 Novartis Corporate Summary
  7.3.2 Novartis Business Overview
  7.3.3 Novartis Drugs for Oncology Major Product Offerings
  7.3.4 Novartis Drugs for Oncology Revenue in Global Market (2017-2022)
  7.3.5 Novartis Key News
7.4 Bristol-Myers Squibb
  7.4.1 Bristol-Myers Squibb Corporate Summary
  7.4.2 Bristol-Myers Squibb Business Overview
  7.4.3 Bristol-Myers Squibb Drugs for Oncology Major Product Offerings
  7.4.4 Bristol-Myers Squibb Drugs for Oncology Revenue in Global Market (2017-2022)
  7.4.5 Bristol-Myers Squibb Key News
7.5 Johnson & Johnson
  7.5.1 Johnson & Johnson Corporate Summary
  7.5.2 Johnson & Johnson Business Overview
  7.5.3 Johnson & Johnson Drugs for Oncology Major Product Offerings
  7.5.4 Johnson & Johnson Drugs for Oncology Revenue in Global Market (2017-2022)
  7.5.5 Johnson & Johnson Key News
7.6 Merck & Co.
  7.6.1 Merck & Co. Corporate Summary
  7.6.2 Merck & Co. Business Overview
  7.6.3 Merck & Co. Drugs for Oncology Major Product Offerings
  7.6.4 Merck & Co. Drugs for Oncology Revenue in Global Market (2017-2022)
  7.6.5 Merck & Co. Key News
7.7 AstraZeneca
  7.7.1 AstraZeneca Corporate Summary
  7.7.2 AstraZeneca Business Overview
  7.7.3 AstraZeneca Drugs for Oncology Major Product Offerings
  7.7.4 AstraZeneca Drugs for Oncology Revenue in Global Market (2017-2022)
  7.7.5 AstraZeneca Key News
7.8 Pfizer
  7.8.1 Pfizer Corporate Summary
  7.8.2 Pfizer Business Overview
  7.8.3 Pfizer Drugs for Oncology Major Product Offerings
  7.8.4 Pfizer Drugs for Oncology Revenue in Global Market (2017-2022)
  7.8.5 Pfizer Key News
7.9 Amgen
  7.9.1 Amgen Corporate Summary
  7.9.2 Amgen Business Overview
  7.9.3 Amgen Drugs for Oncology Major Product Offerings
  7.9.4 Amgen Drugs for Oncology Revenue in Global Market (2017-2022)
  7.9.5 Amgen Key News
7.10 Eli Lilly
  7.10.1 Eli Lilly Corporate Summary
  7.10.2 Eli Lilly Business Overview
  7.10.3 Eli Lilly Drugs for Oncology Major Product Offerings
  7.10.4 Eli Lilly Drugs for Oncology Revenue in Global Market (2017-2022)
  7.10.5 Eli Lilly Key News
7.11 AbbVie
  7.11.1 AbbVie Corporate Summary
  7.11.2 AbbVie Business Overview
  7.11.3 AbbVie Drugs for Oncology Major Product Offerings
  7.11.4 AbbVie Drugs for Oncology Revenue in Global Market (2017-2022)
  7.11.5 AbbVie Key News
7.12 Takeda
  7.12.1 Takeda Corporate Summary
  7.12.2 Takeda Business Overview
  7.12.3 Takeda Drugs for Oncology Major Product Offerings
  7.12.4 Takeda Drugs for Oncology Revenue in Global Market (2017-2022)
  7.12.5 Takeda Key News
7.13 Astellas
  7.13.1 Astellas Corporate Summary
  7.13.2 Astellas Business Overview
  7.13.3 Astellas Drugs for Oncology Major Product Offerings
  7.13.4 Astellas Drugs for Oncology Revenue in Global Market (2017-2022)
  7.13.5 Astellas Key News
7.14 Ipsen
  7.14.1 Ipsen Corporate Summary
  7.14.2 Ipsen Business Overview
  7.14.3 Ipsen Drugs for Oncology Major Product Offerings
  7.14.4 Ipsen Drugs for Oncology Revenue in Global Market (2017-2022)
  7.14.5 Ipsen Key News
7.15 Sanofi
  7.15.1 Sanofi Corporate Summary
  7.15.2 Sanofi Business Overview
  7.15.3 Sanofi Drugs for Oncology Major Product Offerings
  7.15.4 Sanofi Drugs for Oncology Revenue in Global Market (2017-2022)
  7.15.5 Sanofi Key News
7.16 Bayer
  7.16.1 Bayer Corporate Summary
  7.16.2 Bayer Business Overview
  7.16.3 Bayer Drugs for Oncology Major Product Offerings
  7.16.4 Bayer Drugs for Oncology Revenue in Global Market (2017-2022)
  7.16.5 Bayer Key News
7.17 Biogen Idec
  7.17.1 Biogen Idec Corporate Summary
  7.17.2 Biogen Idec Business Overview
  7.17.3 Biogen Idec Drugs for Oncology Major Product Offerings
  7.17.4 Biogen Idec Drugs for Oncology Revenue in Global Market (2017-2022)
  7.17.5 Biogen Idec Key News
7.18 Teva
  7.18.1 Teva Corporate Summary
  7.18.2 Teva Business Overview
  7.18.3 Teva Drugs for Oncology Major Product Offerings
  7.18.4 Teva Drugs for Oncology Revenue in Global Market (2017-2022)
  7.18.5 Teva Key News
7.19 Otsuka
  7.19.1 Otsuka Corporate Summary
  7.19.2 Otsuka Business Overview
  7.19.3 Otsuka Drugs for Oncology Major Product Offerings
  7.19.4 Otsuka Drugs for Oncology Revenue in Global Market (2017-2022)
  7.19.5 Otsuka Key News
7.20 Eisai
  7.20.1 Eisai Corporate Summary
  7.20.2 Eisai Business Overview
  7.20.3 Eisai Drugs for Oncology Major Product Offerings
  7.20.4 Eisai Drugs for Oncology Revenue in Global Market (2017-2022)
  7.20.5 Eisai Key News
7.21 Merck KGaA
  7.21.1 Merck KGaA Corporate Summary
  7.21.2 Merck KGaA Business Overview
  7.21.3 Merck KGaA Drugs for Oncology Major Product Offerings
  7.21.4 Merck KGaA Drugs for Oncology Revenue in Global Market (2017-2022)
  7.21.5 Merck KGaA Key News
7.22 Gilead Sciences
  7.22.1 Gilead Sciences Corporate Summary
  7.22.2 Gilead Sciences Business Overview
  7.22.3 Gilead Sciences Drugs for Oncology Major Product Offerings
  7.22.4 Gilead Sciences Drugs for Oncology Revenue in Global Market (2017-2022)
  7.22.5 Gilead Sciences Key News

8 CONCLUSION

9 APPENDIX

9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Drugs for Oncology Market Opportunities & Trends in Global Market
Table 2. Drugs for Oncology Market Drivers in Global Market
Table 3. Drugs for Oncology Market Restraints in Global Market
Table 4. Key Players of Drugs for Oncology in Global Market
Table 5. Top Drugs for Oncology Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Drugs for Oncology Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Drugs for Oncology Revenue Share by Companies, 2017-2022
Table 8. Global Companies Drugs for Oncology Product Type
Table 9. List of Global Tier 1 Drugs for Oncology Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Drugs for Oncology Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type – Global Drugs for Oncology Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Drugs for Oncology Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Drugs for Oncology Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application – Global Drugs for Oncology Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Drugs for Oncology Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Drugs for Oncology Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region – Global Drugs for Oncology Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Drugs for Oncology Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Drugs for Oncology Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Drugs for Oncology Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Drugs for Oncology Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Drugs for Oncology Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Drugs for Oncology Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Drugs for Oncology Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Drugs for Oncology Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Drugs for Oncology Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Drugs for Oncology Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Drugs for Oncology Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Drugs for Oncology Revenue, (US$, Mn), 2023-2028
Table 30. Roche Corporate Summary
Table 31. Roche Drugs for Oncology Product Offerings
Table 32. Roche Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 33. Celgene Corporate Summary
Table 34. Celgene Drugs for Oncology Product Offerings
Table 35. Celgene Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 36. Novartis Corporate Summary
Table 37. Novartis Drugs for Oncology Product Offerings
Table 38. Novartis Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 39. Bristol-Myers Squibb Corporate Summary
Table 40. Bristol-Myers Squibb Drugs for Oncology Product Offerings
Table 41. Bristol-Myers Squibb Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 42. Johnson & Johnson Corporate Summary
Table 43. Johnson & Johnson Drugs for Oncology Product Offerings
Table 44. Johnson & Johnson Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 45. Merck & Co. Corporate Summary
Table 46. Merck & Co. Drugs for Oncology Product Offerings
Table 47. Merck & Co. Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 48. AstraZeneca Corporate Summary
Table 49. AstraZeneca Drugs for Oncology Product Offerings
Table 50. AstraZeneca Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 51. Pfizer Corporate Summary
Table 52. Pfizer Drugs for Oncology Product Offerings
Table 53. Pfizer Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 54. Amgen Corporate Summary
Table 55. Amgen Drugs for Oncology Product Offerings
Table 56. Amgen Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 57. Eli Lilly Corporate Summary
Table 58. Eli Lilly Drugs for Oncology Product Offerings
Table 59. Eli Lilly Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 60. AbbVie Corporate Summary
Table 61. AbbVie Drugs for Oncology Product Offerings
Table 62. AbbVie Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 63. Takeda Corporate Summary
Table 64. Takeda Drugs for Oncology Product Offerings
Table 65. Takeda Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 66. Astellas Corporate Summary
Table 67. Astellas Drugs for Oncology Product Offerings
Table 68. Astellas Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 69. Ipsen Corporate Summary
Table 70. Ipsen Drugs for Oncology Product Offerings
Table 71. Ipsen Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 72. Sanofi Corporate Summary
Table 73. Sanofi Drugs for Oncology Product Offerings
Table 74. Sanofi Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 75. Bayer Corporate Summary
Table 76. Bayer Drugs for Oncology Product Offerings
Table 77. Bayer Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 78. Biogen Idec Corporate Summary
Table 79. Biogen Idec Drugs for Oncology Product Offerings
Table 80. Biogen Idec Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 81. Teva Corporate Summary
Table 82. Teva Drugs for Oncology Product Offerings
Table 83. Teva Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 84. Otsuka Corporate Summary
Table 85. Otsuka Drugs for Oncology Product Offerings
Table 86. Otsuka Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 87. Eisai Corporate Summary
Table 88. Eisai Drugs for Oncology Product Offerings
Table 89. Eisai Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 90. Merck KGaA Corporate Summary
Table 91. Merck KGaA Drugs for Oncology Product Offerings
Table 92. Merck KGaA Drugs for Oncology Revenue (US$, Mn), (2017-2022)
Table 93. Gilead Sciences Corporate Summary
Table 94. Gilead Sciences Drugs for Oncology Product Offerings
Table 95. Gilead Sciences Drugs for Oncology Revenue (US$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Drugs for Oncology Segment by Type in 2021
Figure 2. Drugs for Oncology Segment by Application in 2021
Figure 3. Global Drugs for Oncology Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Drugs for Oncology Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Drugs for Oncology Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Drugs for Oncology Revenue in 2021
Figure 8. By Type - Global Drugs for Oncology Revenue Market Share, 2017-2028
Figure 9. By Application - Global Drugs for Oncology Revenue Market Share, 2017-2028
Figure 10. By Region - Global Drugs for Oncology Revenue Market Share, 2017-2028
Figure 11. By Country - North America Drugs for Oncology Revenue Market Share, 2017-2028
Figure 12. US Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Drugs for Oncology Revenue Market Share, 2017-2028
Figure 16. Germany Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 17. France Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Drugs for Oncology Revenue Market Share, 2017-2028
Figure 24. China Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 28. India Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Drugs for Oncology Revenue Market Share, 2017-2028
Figure 30. Brazil Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Drugs for Oncology Revenue Market Share, 2017-2028
Figure 33. Turkey Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Drugs for Oncology Revenue, (US$, Mn), 2017-2028
Figure 37. Roche Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Celgene Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Novartis Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Bristol-Myers Squibb Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. Johnson & Johnson Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Merck & Co. Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. AstraZeneca Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Pfizer Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Amgen Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Eli Lilly Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 47. AbbVie Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 48. Takeda Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 49. Astellas Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 50. Ipsen Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 51. Sanofi Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 52. Bayer Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 53. Biogen Idec Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 54. Teva Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 55. Otsuka Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 56. Eisai Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 57. Merck KGaA Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 58. Gilead Sciences Drugs for Oncology Revenue Year Over Year Growth (US$, Mn) & (2017-2022)